Target trial emulation is getting harder to ignore in HTA: registry-based RWD shifted the ICER for post-first-line RA biologics from ~£34.7k to ~£46.8k/QALY.
https://www.mattheneus.com/editorial/target-trial-emulation-rwd-cost-effectiveness-hta-playbook-2026-04-03 #HTA #RWE #HealthEconomics
Target Trial Emulation May Be the Missing Bridge Between Real-World Data and Cost-Effectiveness in Health Technology Assessment
On 3 April 2026, Singh and colleagues published a Med Decision Making study showing that target trial emulation using registry-based real-world data changed the estimated cost effectiveness of biologic treatment after first-line failure in rheumatoid arthritis, lifting the incremental cost-effectiveness ratio from about £34,700 per quality-adjusted life-year in the randomized-trial-only analysis to about £46,800 when real-world evidence informed the estimate.
CAR-T access is no longer just a clinical story; HTA timing and cost-effectiveness design now shape who gets to market and when.
https://www.mattheneus.com/editorial/car-t-global-hta-access-lag-cost-effectiveness-playbook-2026-04-02
#HTA #HealthEconomics #Pharma
Commercial chimeric antigen receptor (CAR) T-cell access now depends on earlier health technology assessment (HTA) and cost-effectiveness design
A new 2 April 2026 Blood analysis shows that commercial chimeric antigen receptor (CAR) T-cell access is being constrained as much by health technology assessment (HTA) timing and cost-effectiveness uncertainty as by manufacturing, forcing evidence teams to pre-build comparative and economic strategy before approval.
HTA evidence teams are hitting a fragmentation wall: ITC, MAIC, NMA, RWE, modelling, and reporting now need one traceable workflow, not stitched-together handoffs.
https://www.mattheneus.com/editorial/abangelabs-hta-studio-itc-foundation-end-to-end-hta-evidence-platform-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #HealthEconomics
AbangeLabs HTA Studio: From ITC Foundation to End-to-End HTA Evidence Platform
Health technology assessment (HTA) evidence teams are increasingly asked to deliver multi-method evidence packages spanning indirect treatment comparison (ITC), matching-adjusted indirect comparison (MAIC), network meta-analysis (NMA), economic modelling, and reporting. This article examines why fragmented execution is becoming a methodological governance risk and how AbangeLabs HTA Studio addresses that problem through documented current capabilities.
HTA submissions keep breaking where comparative evidence meets the economic model. If the lineage is not traceable, cost-effectiveness and budget-impact claims turn fragile fast.
https://www.mattheneus.com/editorial/hta-submissions-comparative-evidence-economic-model-lineage-problem-2026-04-02 #HTA #HealthEconomics #RegulatoryAffairs
Health technology assessment submissions now face a comparative-evidence to economic-model lineage problem
Health technology assessment (HTA) teams increasingly need cost-effectiveness and budget-impact outputs that remain directly traceable to the comparative evidence behind them. This article examines why broken lineage between analysis and modelling has become a submission risk and how AbangeLabs HTA Studio addresses that integration problem through verified current capabilities.
Eastern Europe and Central Asia need a health technology assessment (HTA) capacity-building playbook, not one-off pilots
A 30 March 2026 International Journal of Technology Assessment in Health Care review shows that Eastern Europe and Central Asia are moving toward broader health technology assessment (HTA) use, but uneven staffing, training, and governance mean evidence teams need reusable cross-market comparative and economic packages rather than one-off country submissions.
Germany opens reimbursable Long/Post-COVID off-label use for four medicines
Germany's Federal Joint Committee has moved four Long/Post-COVID off-label recommendations into reimbursable care. The evidence basis is uneven across the package: metformin is anchored in the COVID-OUT randomised controlled trial, while ivabradine, vortioxetine and agomelatine rely on smaller symptom-specific studies with important transferability and bias questions.
Infant and toddler utility measurement is becoming a first-order cost-effectiveness design problem
On 1 April 2026, Quality of Life Research published a recommendations paper on measuring health-related quality of life in infants and toddlers and a companion empirical study using the EuroQol toddler and infant populations instrument in young children. Together they sharpen a familiar but under-managed market-access risk: if utility evidence for children under 5 is weak, proxy-reported, or mapped late, the cost-effectiveness model becomes fragile.
NICE EQ-5D-5L value set move resets cost-effectiveness governance for 2026 submissions
NICE's 25 March 2026 methods blog confirms a transition toward the newer EQ-5D-5L value set, with a formal implementation consultation expected in April through the modular update pathway. For market access and evidence teams, this is a near-term trigger to re-baseline health utility assumptions before finalising cost-effectiveness and budget impact narratives.
Single-Arm Evidence and Economic Extrapolation for Gene Therapies: A Cross-HTA Governance Playbook
Two FDA approvals for ultra-rare disease gene therapies in March 2026 crystallise a structural challenge that spans every major HTA jurisdiction: regulatory approval on single-arm evidence does not generate the comparative data that HTA bodies require.
AbangeLabs
Jan R. Boehnke